Literature DB >> 15657211

Myocardial metabolic manipulation: a new therapeutic approach in heart failure?

E O'Meara, J J V McMurray.   

Abstract

Myocardial metabolic manipulation using drugs such as trimetazidine may offer a new therapeutic approach to the treatment of heart failure.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15657211      PMCID： PMC1768694          DOI： 10.1136/hrt.2004.041756

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  10 in total

1.  Is it time for a randomized trial of surgical treatment of ischemic heart failure?

Authors:  R H Jones
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

2.  Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy.

Authors:  P Di Napoli; A A Taccardi; A Barsotti
Journal:  Heart       Date:  2005-02       Impact factor: 5.994

3.  Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure.

Authors:  T R Wallhaus; M Taylor; T R DeGrado; D C Russell; P Stanko; R J Nickles; C K Stone
Journal:  Circulation       Date:  2001-05-22       Impact factor: 29.690

4.  The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.

Authors:  P F Kantor; A Lucien; R Kozak; G D Lopaschuk
Journal:  Circ Res       Date:  2000-03-17       Impact factor: 17.367

5.  Fatty acid oxidation enzyme gene expression is downregulated in the failing heart.

Authors:  M N Sack; T A Rader; S Park; J Bastin; S A McCune; D P Kelly
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

Review 6.  Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.

Authors:  Leong Lee; John Horowitz; Michael Frenneaux
Journal:  Eur Heart J       Date:  2004-04       Impact factor: 29.983

7.  Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.

Authors:  Bernard R Chaitman; Carl J Pepine; John O Parker; Jaroslav Skopal; Galina Chumakova; Jerzy Kuch; Whedy Wang; Sandra L Skettino; Andrew A Wolff
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

8.  Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure.

Authors:  Inga S Thrainsdottir; Helene von Bibra; Klas Malmberg; Lars Rydén
Journal:  J Cardiovasc Pharmacol       Date:  2004-07       Impact factor: 3.105

Review 9.  The heart failure revascularisation trial (HEART): rationale, design and methodology.

Authors:  J G F Cleland; N Freemantle; S G Ball; R S Bonser; P Camici; S Chattopadhyay; D Dutka; J Eastaugh; J Hampton; S Large; M S Norell; D J Pennell; J Pepper; S Sanda; R Senior; D Smith
Journal:  Eur J Heart Fail       Date:  2003-06       Impact factor: 15.534

10.  Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Barbara Sposato; Giuseppe Mercuro; Massimo Fini
Journal:  Cardiovasc Diabetol       Date:  2003-11-28       Impact factor: 9.951
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.